PLRZ Company Profile and Key Details

PLRZ has shown sold momentum, gaining 6.19% over the past week and 130.49% over the past quarter, though year-to-date performance is up 71.85%. Short-term trend indicators are bearishly aligned (SMA20 0.84%, SMA50 7.45%, SMA200 27.1%). The stock’s 14-day RSI is 51.3 (neutral), while the ATR of 1.54 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.39% below its high and over 375.35% above its low. Average 10-day trading volume of 100.26 thousand shares is significantly above the 3-month average of 62.80 thousand, indicating heightened recent market interest.

Polyrizon Ltd. has 2.08 million shares outstanding. The public float is 1.36 million shares, elevated short interest at 3.08% of float. This equals 63.32 thousand shares. The short ratio is 1.15 days. Institutional investors hold 7.19% of the float. Insiders own 0.83%. Izraeli Tomer holds 31.51 thousand shares, Adler Oz has 19.85 thousand shares and Turgeman Tidhar has 17.52 thousand shares. Over the past six months, insider transactions show net selling. They sold 11.65 thousand shares across 6 transactions.

Polyrizon Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.81. This means the shares are trading above this model’s fair value.

Polyrizon Ltd. (NASDAQ:PLRZ) closed at $11.03 USD, losing -$0.20 (-1.78%) from the previous close of $11.23. The stock is currently mid-range between its 52-week high and low $2.88 and $18.20. With a market capitalization of about $12.36 million, Polyrizon Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.34). Key stats such as the average daily volume over the past year has been around 67.45 thousand shares, in line with its 52-week average. Headquartered in Ra'anana, TA, Polyrizon Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tomer Izraeli, the company employs approximately 6 people and listed since October 29, 2024. Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays.

Polyrizon Ltd. trades at a P/E ratio of -3.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.84 suggesting the stock is closer to book value. The P/FCF stands at -3.04, also below market averages.

Our AI price prediction model suggests that Polyrizon Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.17%, with price expected at $11.38 by September 25, 2026, within a range of $9.80 to $12.96 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 10, 2026, with a range of $0.00 to $22.15. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 10, 2027, within a range of $0.00 to $58.08.

Polyrizon Ltd. (NASDAQ:PLRZ) shares are up 71.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Polyrizon Ltd. trading at a premium to the broader market with a P/E of -3.16. Our AI forecast model points to short-term strength (3.17% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.